CDER Reviewers Showcase Speed In 2019 With 11 Novel Drugs Approved Within Six Months
Executive Summary
Median review time held steady in 2019, but the percentage of NDAs the US FDA approved within six months jumped compared to recent years, a performance upswing all the more impressive because of the relatively high number of applications involved.
You may also be interested in...
Long Hot Summer For Novel Drug Reviews Forecast At US FDA
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Neuroscience Challenges Oncology For Top Spot In CDER’s 2019 Novel Approvals
Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.
US FDA’s Breakneck Approval Pace Clashes With Advisory Committee Mandate
FDA has approved more than 100 novel molecules in the past two years, almost all of them without an advisory committee stop. Is it time to revisit a 2007 law that was intended to assure a public vetting of NMEs prior to approval?
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests:
